Factors Associated with COVID-19 Breakthrough Infection in the Pre-Omicron Era Among Vaccinated Patients with Rheumatic Diseases: A Cohort Study
Patel et al.,
Factors Associated with COVID-19 Breakthrough Infection in the Pre-Omicron Era Among Vaccinated Patients with..,
medRxiv, doi:10.1101/2022.07.13.22277606 (Preprint)
Retrospective 11,468 vaccinated rheumatic disease patients in the USA, showing lower risk of COVID-19 with HCQ/CQ use compared with all other treatments. Adjusted results are only provided with respect to specific other treatments.
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details.
risk of case, 46.3% lower, RR 0.54, p = 0.001, treatment 28 of 18,358 (0.2%), control 223 of 78,509 (0.3%), cases vs. total person-months, unadjusted.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Patel et al., 15 Jul 2022, retrospective, USA, preprint, mean age 60.0, 12 authors.
Contact:
zswallace@mgh.harvard.edu, jsparks@bwh.harvard.edu.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2022.07.13.22277606; this version posted July 15, 2022. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Breakthrough infections in rheumatic disease patients
Running Head: Breakthrough infections in rheumatic disease patients
Title: Factors Associated with COVID-19 Breakthrough Infection in the Pre-Omicron Era
Among Vaccinated Patients with Rheumatic Diseases: A Cohort Study
Authors: Naomi J. Patel, MD1,4; Xiaosong Wang, MS2, Xiaoqing Fu, MS1; Yumeko Kawano,
MD2,4; Claire Cook, MPH1,3; Kathleen M.M. Vanni, BA2; Grace Qian, BA&Sc2; Emily
Banasiak, BA2; Emily Kowalski, BS2; Yuqing Zhang, ScD1,3,4; Jeffrey A. Sparks, MD,
MMSc2,4*; Zachary S. Wallace, MD, MSc1,3,4*
*These authors contributed equally to this work (co-last authors).
Affiliations:
1
Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston,
MA, USA (Rheumatology Associates, 55 Fruit Street, Boston, MA, 02114)
2
Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital,
Boston, MA, USA (60 Fenwood Road, Boston, MA, 02115)
3
Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts
General Hospital, Boston, MA, USA (The Mongan Institute, 100 Cambridge Street, Suite 1600,
Boston, MA, 02114)
4
Harvard Medical School, Boston, MA.
Financial Support
1
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2022.07.13.22277606; this version posted July 15, 2022. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Breakthrough infections in rheumatic disease patients
NJP is supported by the Rheumatology Research Foundation. JAS is funded by NIH/NIAMS
(grant numbers, R01 AR077607, P30 AR070253, and P30 AR072577), the R. Bruce and Joan M.
Mickey Research Scholar Fund, and the Llura Gund Award for Rheumatoid Arthritis Research
and Care. ZSW is funded by NIH/NIAMS [K23AR073334 and R03AR078938].
Declaration of interests
NJP reports consulting fees from FVC Health unrelated to the current work. JAS reports research
support from Bristol Myers Squibb and consultancy fees from AbbVie, Amgen, Boehringer
Ingelheim, Bristol Myers Squibb, Gilead, Inova Diagnostics, Janssen, Optum, and Pfizer. ZSW
reports research support from Bristol-Myers Squibb and Principia/Sanofi and consulting fees
from Zenas Biopharma, Horizon, Sanofi, Shionogi, Viela Bio, and MedPace. All other authors
report no competing interests.
Corresponding authors:
Zachary S. Wallace, MD, MSc
Clinical Epidemiology Program
Division of Rheumatology, Allergy, and Immunology
Massachusetts General Hospital
100 Cambridge Street, 16th Floor
Boston, MA 02114
617-724-2507
zswallace@mgh.harvard.edu
@zach_wallace_md
2
medRxiv preprint doi: https://doi.org/10.1101/2022.07.13.22277606; this version posted July 15, 2022. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit